422 related articles for article (PubMed ID: 32610115)
1. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
[TBL] [Abstract][Full Text] [Related]
2. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
3. Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.
Leung HH; Puspanathan P; Chan AW; Nik Mustapha NR; Wong VW; Chan WK
J Gastroenterol Hepatol; 2022 Jun; 37(6):1131-1138. PubMed ID: 35362158
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
5. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
8. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
9. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.
Colca JR; McDonald WG; Adams WJ
Expert Opin Investig Drugs; 2018 Jul; 27(7):631-636. PubMed ID: 29950116
[TBL] [Abstract][Full Text] [Related]
10. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
Brunt EM; Clouston AD; Goodman Z; Guy C; Kleiner DE; Lackner C; Tiniakos DG; Wee A; Yeh M; Leow WQ; Chng E; Ren Y; Boon Bee GG; Powell EE; Rinella M; Sanyal AJ; Neuschwander-Tetri B; Younossi Z; Charlton M; Ratziu V; Harrison SA; Tai D; Anstee QM
J Hepatol; 2022 May; 76(5):1030-1041. PubMed ID: 35090960
[TBL] [Abstract][Full Text] [Related]
11. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
12. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Liu F; Goh GB; Tiniakos D; Wee A; Leow WQ; Zhao JM; Rao HY; Wang XX; Wang Q; Wan WK; Lim KH; Romero-Gomez M; Petta S; Bugianesi E; Tan CK; Harrison SA; Anstee QM; Chang PJ; Wei L
Hepatology; 2020 Jun; 71(6):1953-1966. PubMed ID: 31600834
[TBL] [Abstract][Full Text] [Related]
13. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
14. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
[TBL] [Abstract][Full Text] [Related]
15. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Bril F; Barb D; Lomonaco R; Lai J; Cusi K
J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Musso G; Cassader M; Paschetta E; Gambino R
JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
[TBL] [Abstract][Full Text] [Related]
17. Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.
Ratziu V; Francque S; Behling CA; Cejvanovic V; Cortez-Pinto H; Iyer JS; Krarup N; Le Q; Sejling AS; Tiniakos D; Harrison SA
Hepatology; 2024 Jul; 80(1):173-185. PubMed ID: 38112484
[TBL] [Abstract][Full Text] [Related]
18. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis.
Kim HP; Idowu MO; Mospan AR; Allmon AG; Roden M; Newsome P; Lok AS; Thuluvath PJ; Taunk J; Fried MW; Sanyal AJ; Barritt AS;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1472-1480. PubMed ID: 34694013
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
